CR 6086

Drug Profile

CR 6086

Alternative Names: CR6086

Latest Information Update: 22 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rottapharm Madaus
  • Developer Rottapharm Biotech
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 26 May 2017 Rottapharm Biotech plans a phase II trial for Rheumatoid arthritis (Combination therapy, Early-stage disease) (NCT03163966)
  • 22 Feb 2017 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in Italy (PO) before February 2017 (Rottapharm Biotech pipeline, February 2017)
  • 22 Feb 2017 Rottapharm Biotech plans a phase II trial for Rheumatoid arthritis (Rottapharm Biotech, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top